The Annals of pharmacotherapy
-
Editorial Review Comparative Study
Human papillomavirus quadrivalent vaccine: a look behind the numbers.
The human papillomavirus (HPV) quadrivalent vaccine was licensed in 2006 for prevention of cervical, vulvar, and vaginal cancers caused by HPV-16 and -18 and genital warts caused by HPV-6 and -11. It is also indicated for prevention of precancerous and dysplastic lesions caused by HPV-6, -11, -16, and -18. ⋯ Careful consideration should be given to these issues by pharmacy and pharmacy professional organizations. To formulate reasonable healthcare guidelines, pharmacists and other healthcare professionals will need to engage policymakers in conversations concerning the vaccine's merits or limitations and the economic impact.